Hangzhou TianMuShan Pharmaceutical EnterpriseLtd Balance Sheet Health
Financial Health criteria checks 3/6
Hangzhou TianMuShan Pharmaceutical EnterpriseLtd has a total shareholder equity of CN¥41.1M and total debt of CN¥104.2M, which brings its debt-to-equity ratio to 253.4%. Its total assets and total liabilities are CN¥333.1M and CN¥292.0M respectively.
Key information
253.4%
Debt to equity ratio
CN¥104.24m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥71.31m |
| Equity | CN¥41.13m |
| Total liabilities | CN¥292.01m |
| Total assets | CN¥333.15m |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 600671's short term assets (CN¥167.5M) do not cover its short term liabilities (CN¥226.3M).
Long Term Liabilities: 600671's short term assets (CN¥167.5M) exceed its long term liabilities (CN¥65.7M).
Debt to Equity History and Analysis
Debt Level: 600671's net debt to equity ratio (80%) is considered high.
Reducing Debt: 600671's debt to equity ratio has increased from 93.4% to 253.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 600671 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 600671 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 44.5% each year.